ABSTRACT
Objective: To discuss the clinical effect of Shugan Jieyu capsules combined with repetitivetranscranial magnetic stimulation (rTMS) on depression during perimenopause and neuroendocrine function. Method: One hundred and thirty-two patients were divided into control groupand observation groupby random number table. Patients (65 cases) in observation group got sertraline hydrochloride tablets, 50 mg/time, 2 times/days. Patients (67 cases) in control group got Shugan Jieyu capsules after breakfast and dinner, 2 grains/time, and treatment of rTMS, 20 minutes/time, 1 time/day. And one course of treatment was 5 days, there were a 2-day interval between two courses. And there were a total of 4 courses in the two groups. Both groups were continuously treated for8 weeks. Degree of depression was evaluated by Hamilton depression scale-17 (HAMD-17). Before and after treatment, scores of Hamilton anxiety scale (HAMA), quality index of sleep in Pittsburgh (PSQI), Kupperman and syndrome of kidney deficiency and stagnation of liver were graded. Levels of follicle stimulating hormone (FSH), Luteinizing hormone (LH), estradiol (E2), 5-serotonin (5-HT), dopamine (DA), norepinephrine (NE) and 5-hydroxyindolyl acetic acid (5-HIAA) were detected, and the safety was evaluated. Result: According to the variance analysis of repeated measurements, after treatment, score of HAMD-17 decreased (Pth day after treatment, score of HAMD-17of observation groupwas lower than that in control group (PPχ2=6.405, Pχ2=5.304, PPConclusion: Shugan Jieyu capsules combined with repetitivetranscranial magnetic stimulation can ameliorate symptoms of depression and anxiety, havea bettereffect than Sertraline hydrochloride tablets, and can regulate levels of sex hormone and monoamine neurotransmitter.
ABSTRACT
Objective To study the effect and safety of Shugan Jieyu capsules combined with olanzapine tablets in the treatment of schizophrenia,and to analyze its effects on the patients’ depressive symptoms.Methods According to the digital table,80 patients with schizophrenia were randomly divided into control group and observation group,40 cases in each group.The control group was treated with olanzapine,while the observation group was given olanzapine combined with Shugan Jieyu capsules.During the treatment,the other antidepressants,antipsychotics and mood stabilizers were prohibited.Results After treatment,the scores of CDSS,PANSS,PSQI and SQLS in the two groups were improved,and the differences were statistically significant(all P ＜ 0.05).The CDSS score was (3.4 ± 2.5) points,PANSS score was (36.2 ± 7.5) points,PSQI score was (3.4 ± 2.5) points and SQLS total score was (79.1 ± 16.2)points in the observation group,which were all better than those in the control group[CDSS score was (2.8 ± 2.0) points,PANSS score was (40.5 ± 8.7) points,PSQI score was (5.8 ± 3.3) points and SQLS total score was (59.4 ± 19.1) points],the differences were statistically significant (t =5.942,2.368,3.666,4.975,all P ＜ 0.05).After treatment,TCHO,TG,SBP,DBP and GLU were decreased in both two groups,but no significant differences were shown compared with before treatment(t =1.265,0.425,1.224,1.236,0.670,all P＞ 0.05),and there were no significant differences between the two groups (all P ＞ 0.05).After treatment,the total effective rate of the control group(67.5％) was lower than 85.0％ of the observation group,the difference was statistically significant (x2 =4.267,P ＜ 0.05).There were no significant difference in the incidence of complications between the two groups(x2 =0.139,0.164,0.105,0.263,0.263,0.180,all P ＞0.05).Conclusion For the treatment of schizophrenia,combined therapy of olanzapine tablets and Shugan Jieyu capsules has significant effect and higher safety,it can improve the patients'depressive symptoms,regulate the body's metabolism and improve their sleep and life quality.
ABSTRACT
Objective To investigate the therapeutic effect of Shugan Jieyu Capsules for the treatment of maintenance hemodialysis patients with insomnia. Methods Forty maintenance hemodialysis patients with insomnia were randomized into observation group and control group by random number table method,20 cases in each group. Patients of the two groups were given conventional maintenance hemodialysis and fundamental treatment for controlling blood pressure and glucose,regulating calcium-phosphorus metabolism,and relieving anemia. And additionally,the control group was treated with Estazolam Tablets orally,and the observation group was treated with Shugan Jieyu Capsules orally. By using Pittsburgh Sleep Quality Index(PSQI)scale,we investigated the changes of the quality of sleep in two groups before and after treatment,and evaluated the therapeutic effect. Results (1)After treatment,PSQI scores of the two groups were obviously decreased,and the difference was significant (P < 0.05 compared with those before treatment). The observation group had stronger effect on decreasing PSQI scores than the control group,the difference being significant(P < 0.05).(2)The total effective rate of the observation group was 90.0% and that of the control group was 75.0%, the difference being significant (P<0.05). (3)During the treatment,adverse reaction of morning dizziness or drug dependence was not shown. Conclusion Shugan Jieyu Capsules exert certain therapeutic effect for the treatment of maintenance hemodialysis patients with insomnia by improving the quality of sleep.
ABSTRACT
Objective:To evaluate and compare the efficacy and safety of Shugan Jieyu capsules and hydrochloride Venlafaxine capsules in the treatment of depression. Methods:Totally 50 cases of patients with depression were randomly divided into the observa-tion group (n=26) and the control group (n=24). The observation group was treated with 2 Shugan Jieyu capsules in the morning and in the evening, while the control group was treated with hydrochloride Venlafaxine capsules at the dose of 75-150 mg·d-1,six weeks as a course of treatment. Hamilton Depression Scale ( HAMD) and Treatment Emergent Symptom Scale ( TESS) were used in the evaluation before the treatment and 2, 4 and 6 weeks after the treatment. Results:HAMD scores of the two groups were significant-ly decreased after the treatment (P0. 05). The total efficacy of Shugan Jieyu capsules and hydrochloride Venlafaxine capsules was 88. 46% and 87. 5%, respectively, and there was no significant difference (P>0. 05). TESS scores of the observation group were significantly lower than those of the control group after the 2, 4 and 6-week treatment (P<0. 01). The incidence of adverse reactions of Shugan Jieyu capsules (42. 31%) was obviously lower than that of hydrochloride Venlafaxine capsules (70. 83%, P<0. 01). Con-clusion:Shugan Jieyu capsules are safe and effective in the treatment of depression.
ABSTRACT
This study was aimed to observe the safety and effectiveness ofShugan Jieyu Capsules in the treatment of vasovagal syncope (VVS) with mild-to-moderate depression and anxiety, and to compare the effect with Flupentixol and Melitracen Tablets. A total of 89 VVS cases with mild-to-moderate depression and anxiety were randomly divided into 3 groups, which were group A (Shugan Jieyu Capsules group), group B (Flupentixol and Melitracen Tablets) and group C (control group). Based on the conventional therapy of VVS treatment, treatments were given to all three groups for 8 weeks. And the negative conversion ratio of VVS in each group was observed. Hamilton Depression Scale (HAMD 24 items) and Hamilton Anxiety Scale (HAMA) were evaluated for the calculation of reductive rate. Treatment emergent symptoms scale (TESS) was used in the evaluation of adverse reactions of both medications during the treatment. In the 12-month follow-up after treatment, the recurrence rate of syncope was observed in each group. The results showed that compared with pretreatment, HAMD-24 and HAMA scores of group A and group B after treatment were significantly reduced (P < 0.05). Compared with group C, the heat-up tilt testing-negative rate, HAMD-24 and HAMA reductive rate of group A and group B after treatment were significantly increased (P < 0.05). Compared with group B, the negative rate, HAMD-24 and HAMA reductive rate of group A were more significant (P < 0.05). After treatment, scores for TESS of group A was significantly lower than group B (P< 0.05). In the 24-month follow-up, the recurrence rate of syncope of group A and group B was significantly lower than group C (P < 0.05); and group A was obviously better than group B (P < 0.05). It was concluded thatShugan Jieyu Capsules can be used in the treatment of VVS with mild-to-moderate depression and anxiety. Its effectiveness and safety may be better than Flupentixol and Melitracen Tablets.